Poster 1
‘Specific immune response induced by immunization with autologous epidermal growth factor receptor-extracellular domain’
B. Sanchez Ramirez et al. (Center of Molecular Immunology, Havana, Cuba)

Poster 2
‘Analysis of leukocytes in patients immunized with autologous IFN-gamma producing glioma cells’
E. Visse et al. (University Hospital, Lund, Sweden)

Poster 3
‘Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation’
A.-K. Roos et al. (Cancer Center Karolinska, Stockholm, Sweden)

Poster 4
‘Enhanced survival of mice vaccinated with GMCSF-transfected mouse glioma cells and recombinant IFNγ’
K. Enell et al. (University Hospital, Lund, Sweden)

Poster 5
‘Dendritic cell immunotherapy for advanced metastatic melanoma: Interim report’
N. Wilson et al. (St George’s Hospital, University of London, UK)

Poster 6
‘Different methods to load murine dendritic cells to induce T cell responses in mouse model’
S. Moreno et al. (Cancer Center Karolinska, Stockholm, Sweden)

Poster 7
‘Automated electroporation device for use in the clinic’
T.E. Tjelle et al. (INOVIO AS, Oslo, Norway)

Poster 8
‘Preclinical and clinical development of a DC-based melanoma therapeutic vaccine’
M. Salcedo et al. (IDM, Paris, France)

Poster 9
‘CD40L gene assembled to immune-reconstituted influenza virosome (IRIV) enhances the immunological and protective activity of a CEA anti-cancer vaccine’
M.G. Cusi et al. (Siena University School of Medicine, Italy)

Poster 10
‘T cell activation and anti-tumor activity of IL-12 transduced and tumor antigen loaded mouse dendritic cells at different stages of maturation’
J. Rossowska et al. (Polish Academy of Sciences, Wroclaw, Poland)

Poster 11
‘Do bacteriophages support anti-tumor response initiated by DC-based vaccine in murine transplantable colon carcinoma?’
E. Pajtasz-Piasecka et al. (Polish Academy of Sciences, Wroclaw, Poland)

Poster 12
‘Antitumor activity of IL-12 transduced mouse dendritic cells vaccine’
E. Pajtasz-Piasecka et al. (Polish Academy of Sciences, Wroclaw, Poland)

Poster 13
‘Dendritic cells loaded with Her2 virus-like particles prevents outgrowth of Her2 expressing tumors’
K. Tegerstedt et al. (Karolinska Institute, Stockholm, Sweden)

Poster 14
‘Therapeutic vaccination against papillomavirus using a non-replicative vaccinia virus expressing E6 and E7 genes of HPV16 in combination with chemotherapy’
N. Silvestra et al. (Transgene SA, Strasbourg, France)

Poster 15
‘CpG admixed with irradiated tumor cells could effectively prevent tumor development in mice’
V. Stegel et al. (Institute of Oncology, Ljubljana, Slovenia)

Poster 16
‘Impact of microparticles phagocytosis on the phenotype and function of immature dendritic cells’
D.R. Lorenzen et al. (Institute for Tumor Therapy, Duderstadt, Germany)

Poster 17
‘HLA-A2/CEA₆₉₄ specific T cells: Antigen variants explain probable failures of tumor recognition’
P. Alves et al. (Ludwig Institute for Cancer Research, Lausanne, Switzerland)

Poster 18
‘Cryopreservedα-galactosylceramide pulsed monocyte derived dendritic cell vaccines retain in vitro and in vivo activity’
T. Hagi et al. (University of Queensland, Brisbane, Australia)

Poster 19
‘Topical pre-treatment with the TLR7 agonist imiquimod does not enhance migration of mature cells in vivo’
M. Bodman-Smith et al. (St George’s University of London, UK)

Poster 20
‘Differential ability of DC subsets to ingest tumour material is time related’
E. Kovalcsik et al. (St George’s University of London, UK)

Poster 21
‘Combination therapy of topical Aldara and intralesional IL-2 to treat persitent cutaneous and subcutaneous melanoma deposits’
D. Green et al. (St George’s University of London, UK)

Poster 22
‘Characterization of MVA-BN®’
R. Steigerwald et al. (Bavarian Nordic GmbH, Martinsried, Germany)

Poster 23
‘Functionality, magnitude and phenotype of spontaneous peptide specific T-cell responses in cancer patients’
R.B. Sorensen et al. (Danish Cancer Society, Copenhagen, Denmark)

Poster 24
‘Autologous cellular vaccine allows control of cancer immunoediting in a mouse model of plasmacytoma’
S. Sartosis et al. (University of Verona, Italy)

Poster 25
‘Toll like receptor ligands as adjuvants for VLP-induced T cell responses: Different outcomes for different ligands’
K. Schwarz and M.F. Bachmann (Cytos Biotechnology AG, Zurich, Switzerland)

Poster 26
‘Presentation of a standard protocol for clinical grade dendritic cells production’
P.-J. Royer et al. (INSERM U601, Nantes, France)

Poster 27
‘Effects of IFN-gamma on in vitro cultured acute myelogenous leukaemia blasts’
E. Ersvaer et al. (University of Bergen, Norway)

Poster 28
‘IC31, a novel adjuvant, induces potent cellular and humoral immunity’
K. Lingnau et al. (Intercell AG, Vienna, Austria)

Poster 29
‘Carrier technology for targeted transmucosal delivery of therapeutic proteins produced in plants’
D. Florack et al. (Plant Research International BV, Wageningen, The Netherlands)

Poster 30
‘A phase I study of YMB2002, a gonadotropin releasing hormone (GnRH) fusion protein vaccine (NOR-1) with Montanide® ISA51 in men with cancer of the prostate’
S. Thompson et al. (YM Biosciences Inc., Mississauga, Ontario, Canada)

Poster 31
‘Combination therapy of intratumoral administration of dendritic cells and irradiation can induce strong antitumor effect against the squamous cell carcinoma in mice’
Y. Akutsu et al. (Chiba University, Japan)

Poster 32
‘ImmunoVEX^tri-melan: A cancer vaccine for dendritic cell mediated immunotherapy of melanoma’
P. Reay et al. (BioVex Ltd, Abingdon, Cambridge, UK)

Poster 33
‘CD4⁺CD25^high regulatory T cells are enriched in the peripheral blood and tumour tissue of patients with prostate cancer’
A.M. Miller et al. (Karolinska Institute, Stockholm, Sweden)